Klotho Neurosciences, Inc. (KLTO)
| Market Cap | 9.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.21M |
| Shares Out | 21.26M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,830 |
| Open | 0.450 |
| Previous Close | 0.461 |
| Day's Range | 0.440 - 0.490 |
| 52-Week Range | 0.260 - 13.100 |
| Beta | -0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 15, 2025 |
About KLTO
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-r... [Read more]
News
ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein
ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intell...